Economic evaluation of the societal costs of hepatitis B in South Korea

B M Yang, S W Paik, O S Hahn, Deokhee Yi, M S Choi, S Payne

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

BACKGROUND AND AIMS: Hepatitis B (HBV) infection remains a major public health problem in South Korea, and accounts for considerable morbidity and mortality. At present, very little is known about the cost of HBV to the South Korean health-care system and society. The present study was therefore conducted to estimate the total annual cost of HBV infection in South Korea for a given year (1997). METHODS: The study was conducted from the South Korean societal perspective, taking into account the direct and indirect costs of HBV vaccination programs (prevention costs), and those related to the treatment of acute and chronic hepatitis, cirrhosis and liver cancer (disease costs). Several assumptions were made in arriving to actual cost estimates. RESULTS: The total societal cost of HBV in 1997 was 1078.3 billion Won ($US 959.7 million), 142.3 billion Won or 13.2% being attributable to prevention costs and 225.4 billion Won or 20.9% being attributable to indirect costs of HBV-related diseases. The total cost (direct plus indirect) associated with HBV-related diseases to the South Korean society was 936.1 billion Won ($US 833.1 million), of which 45.3% was attributable to cirrhosis-related costs. In terms of disease-related direct costs alone (710.5 billion Won or $US 632.3 million), the estimated annual spending per patient was 1.37 million Won ($US 1219). The direct costs of the HBV disease (prevention and disease treatment, amounting to 782.2 billion Won or $US 696.2 million) is equivalent to 3.2% of the national health-care expenditure for 1997. CONCLUSIONS: This study confirms that HBV is a significant cost burden to the South Korean society, and in the absence of an effective cure reinforces the importance of continued disease prevention via vaccination.
Original languageEnglish
Pages (from-to)301-308
Number of pages8
JournalJournal of Gastroenterology and Hepatology
Volume16
Issue number3
DOIs
Publication statusPublished - 1 Mar 2001

Fingerprint

Republic of Korea
Hepatitis B
Cost-Benefit Analysis
Costs and Cost Analysis
Cost of Illness
Vaccination
Fibrosis
Delivery of Health Care
Chronic Hepatitis
Liver Neoplasms
Health Expenditures
Infection
Liver Diseases
Public Health

Keywords

  • Fibrosis
  • Health Care Costs
  • Hepatitis B
  • Humans
  • Korea
  • Vaccination
  • cost-of-illness analysis
  • hepatitis B
  • vaccination

Cite this

Economic evaluation of the societal costs of hepatitis B in South Korea. / Yang, B M; Paik, S W; Hahn, O S; Yi, Deokhee; Choi, M S; Payne, S.

In: Journal of Gastroenterology and Hepatology, Vol. 16, No. 3, 01.03.2001, p. 301-308.

Research output: Contribution to journalArticle

Yang, B M ; Paik, S W ; Hahn, O S ; Yi, Deokhee ; Choi, M S ; Payne, S. / Economic evaluation of the societal costs of hepatitis B in South Korea. In: Journal of Gastroenterology and Hepatology. 2001 ; Vol. 16, No. 3. pp. 301-308.
@article{5a4af4ce9eeb4908be298991c7274917,
title = "Economic evaluation of the societal costs of hepatitis B in South Korea",
abstract = "BACKGROUND AND AIMS: Hepatitis B (HBV) infection remains a major public health problem in South Korea, and accounts for considerable morbidity and mortality. At present, very little is known about the cost of HBV to the South Korean health-care system and society. The present study was therefore conducted to estimate the total annual cost of HBV infection in South Korea for a given year (1997). METHODS: The study was conducted from the South Korean societal perspective, taking into account the direct and indirect costs of HBV vaccination programs (prevention costs), and those related to the treatment of acute and chronic hepatitis, cirrhosis and liver cancer (disease costs). Several assumptions were made in arriving to actual cost estimates. RESULTS: The total societal cost of HBV in 1997 was 1078.3 billion Won ($US 959.7 million), 142.3 billion Won or 13.2{\%} being attributable to prevention costs and 225.4 billion Won or 20.9{\%} being attributable to indirect costs of HBV-related diseases. The total cost (direct plus indirect) associated with HBV-related diseases to the South Korean society was 936.1 billion Won ($US 833.1 million), of which 45.3{\%} was attributable to cirrhosis-related costs. In terms of disease-related direct costs alone (710.5 billion Won or $US 632.3 million), the estimated annual spending per patient was 1.37 million Won ($US 1219). The direct costs of the HBV disease (prevention and disease treatment, amounting to 782.2 billion Won or $US 696.2 million) is equivalent to 3.2{\%} of the national health-care expenditure for 1997. CONCLUSIONS: This study confirms that HBV is a significant cost burden to the South Korean society, and in the absence of an effective cure reinforces the importance of continued disease prevention via vaccination.",
keywords = "Fibrosis, Health Care Costs, Hepatitis B, Humans, Korea, Vaccination, cost-of-illness analysis, hepatitis B, vaccination",
author = "Yang, {B M} and Paik, {S W} and Hahn, {O S} and Deokhee Yi and Choi, {M S} and S Payne",
year = "2001",
month = "3",
day = "1",
doi = "10.1046/j.1440-1746.2001.02443.x",
language = "English",
volume = "16",
pages = "301--308",
journal = "Journal of Gastroenterology and Hepatology",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Economic evaluation of the societal costs of hepatitis B in South Korea

AU - Yang, B M

AU - Paik, S W

AU - Hahn, O S

AU - Yi, Deokhee

AU - Choi, M S

AU - Payne, S

PY - 2001/3/1

Y1 - 2001/3/1

N2 - BACKGROUND AND AIMS: Hepatitis B (HBV) infection remains a major public health problem in South Korea, and accounts for considerable morbidity and mortality. At present, very little is known about the cost of HBV to the South Korean health-care system and society. The present study was therefore conducted to estimate the total annual cost of HBV infection in South Korea for a given year (1997). METHODS: The study was conducted from the South Korean societal perspective, taking into account the direct and indirect costs of HBV vaccination programs (prevention costs), and those related to the treatment of acute and chronic hepatitis, cirrhosis and liver cancer (disease costs). Several assumptions were made in arriving to actual cost estimates. RESULTS: The total societal cost of HBV in 1997 was 1078.3 billion Won ($US 959.7 million), 142.3 billion Won or 13.2% being attributable to prevention costs and 225.4 billion Won or 20.9% being attributable to indirect costs of HBV-related diseases. The total cost (direct plus indirect) associated with HBV-related diseases to the South Korean society was 936.1 billion Won ($US 833.1 million), of which 45.3% was attributable to cirrhosis-related costs. In terms of disease-related direct costs alone (710.5 billion Won or $US 632.3 million), the estimated annual spending per patient was 1.37 million Won ($US 1219). The direct costs of the HBV disease (prevention and disease treatment, amounting to 782.2 billion Won or $US 696.2 million) is equivalent to 3.2% of the national health-care expenditure for 1997. CONCLUSIONS: This study confirms that HBV is a significant cost burden to the South Korean society, and in the absence of an effective cure reinforces the importance of continued disease prevention via vaccination.

AB - BACKGROUND AND AIMS: Hepatitis B (HBV) infection remains a major public health problem in South Korea, and accounts for considerable morbidity and mortality. At present, very little is known about the cost of HBV to the South Korean health-care system and society. The present study was therefore conducted to estimate the total annual cost of HBV infection in South Korea for a given year (1997). METHODS: The study was conducted from the South Korean societal perspective, taking into account the direct and indirect costs of HBV vaccination programs (prevention costs), and those related to the treatment of acute and chronic hepatitis, cirrhosis and liver cancer (disease costs). Several assumptions were made in arriving to actual cost estimates. RESULTS: The total societal cost of HBV in 1997 was 1078.3 billion Won ($US 959.7 million), 142.3 billion Won or 13.2% being attributable to prevention costs and 225.4 billion Won or 20.9% being attributable to indirect costs of HBV-related diseases. The total cost (direct plus indirect) associated with HBV-related diseases to the South Korean society was 936.1 billion Won ($US 833.1 million), of which 45.3% was attributable to cirrhosis-related costs. In terms of disease-related direct costs alone (710.5 billion Won or $US 632.3 million), the estimated annual spending per patient was 1.37 million Won ($US 1219). The direct costs of the HBV disease (prevention and disease treatment, amounting to 782.2 billion Won or $US 696.2 million) is equivalent to 3.2% of the national health-care expenditure for 1997. CONCLUSIONS: This study confirms that HBV is a significant cost burden to the South Korean society, and in the absence of an effective cure reinforces the importance of continued disease prevention via vaccination.

KW - Fibrosis

KW - Health Care Costs

KW - Hepatitis B

KW - Humans

KW - Korea

KW - Vaccination

KW - cost-of-illness analysis

KW - hepatitis B

KW - vaccination

U2 - 10.1046/j.1440-1746.2001.02443.x

DO - 10.1046/j.1440-1746.2001.02443.x

M3 - Article

VL - 16

SP - 301

EP - 308

JO - Journal of Gastroenterology and Hepatology

JF - Journal of Gastroenterology and Hepatology

SN - 0815-9319

IS - 3

ER -